Calendar pages are rapidly falling away to November 3.

And regardless of the presidential election’s outcome, one of the biggest winners that night could be a recession-resistant industry on the rebound.

American cannabis multistate operators (MSOs) have already enjoyed a sizable bounce from their early 2020 lows…

US Marijuana Chart

The U.S. Marijuana Index is up 156.5% from its March 18 bottom.

And this could merely be the first leg higher of a much larger rally.

Over the next couple of months, the U.S. cannabis market will be on the cusp of getting even bigger. And this November, election night results could send shares of American pot stocks into overdrive.

The Race to $80 Billion

In 2012, there were just two adult-use (or recreational) marijuana markets and 12 medical markets in the U.S.

Today, there are a dozen adult-use markets and more than three dozen medical ones.

US Cannabis Legalization by State

And despite the pandemic, business is booming. Adult-use sales in the country are projected to top $10 billion this year. And medical sales are forecast to be as much as $7 billion.

By 2024, U.S. cannabis sales are already forecast to top $37 billion.

That’s fantastic growth in the face of one of the most disruptive global events in decades.

And to support this, Jushi Holdings (OTC: JUSHF) co-President Erich Mauff recently outlined his company’s record results.

But this November, five more states have legalization measures on the ballot. Arizona, Montana and New Jersey will be voting on adult-use while Mississippi will be voting on medical. South Dakota will be voting on both.

Plus, Pennsylvania Governor Tom Wolf wants the state legislature to legalize adult-use in the face of a budget shortfall.

This is likely to be repeated again and again in the coming months as the pandemic ravages businesses.

On top of that, the Marijuana Opportunity Reinvestment and Expungement (MORE) Act will receive a full floor vote in the U.S. House of Representatives in September. This would remove cannabis from the Controlled Substances Act, as well as expunge some criminal records.

There’s little doubt the bill will pass the House. And that’ll provide a tailwind for cannabis companies. But the updraft could be short-lived.

Last year, the House passed the Secure and Fair Enforcement (SAFE) Banking Act. But the bill stalled in the Republican-controlled Senate.

The next couple of months are going to be important for the American marijuana industry. And if Democrats win the White House or the Senate, expect pot stocks to rocket higher.

But in reality, American MSOs are already winning.

The Biggest Winners

We’re well on our path to an $80 billion U.S. cannabis market by 2030.

But it’s important to understand that American cannabis companies are already scoring big. And the latest quarterly results demonstrate this.

Earlier this year, Green Thumb Industries (OTC: GTBIF) became the first cannabis company to report $100 million in revenue. In its most recent quarter, sales surged 168% to $119.6 million. The MSO has now made more in the first six months of 2020 than it did in all of 2019.

But the crown is awarded to Trulieve Cannabis (OTC: TCNNF). It reported a 109% increase in revenue to $120.8 million. The company also raised full-year guidance to between $465 million and $485 million. That’s almost a $100 million increase from its previous forecast.

It’s the largest cannabis company by revenue.

But the monster performances by American MSOs continued with Curaleaf Holdings (OTC: CURLF), which reported a 142% increase in sales to $117.5 million. Meanwhile, Cresco Labs (OTC: CRLBF) posted 215% year-over-year growth to $94.3 million.

There are no cannabis producers – American or Canadian – as large as those four in terms of revenue. And their share prices this year have left the Horizons Marijuana Life Sciences Index ETF (OTC: HMLSF) in the dust.

American MSOs Chart

American cannabis is enjoying a record year.

Its business has been undented by the pandemic because it was deemed essential.

Despite the dumpster fire that 2020 has been, it’s been a rebound year for cannabis.

But over the next couple of months, the prospects for U.S. MSOs could get exponentially brighter. And that would send their shares on a run unlike anything we’ve seen in years. Even better, the American cannabis market would be large enough to support more than one major MSO. And that’d be good news for investors… especially those with a multiyear time horizon.

Here’s to high returns,


Originally Published by Matthew Carr on

Your favorite MJ Products Delivered To Your Door Right Here!